NuCana Discontinues NuTide:323 Study Following Pre-Planned Initial Analysis And Recommendation From NuTide:323 Study Steering Committee.
Portfolio Pulse from Benzinga Newsdesk
NuCana has decided to discontinue the NuTide:323 study based on a pre-planned initial analysis and recommendation from the study's steering committee. However, the NuTide:701 and NuTide:303 studies will continue, with promising data on NUC-7738 plus Pembrolizumab to be presented at the ESMO Annual Conference.
August 29, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NuCana has discontinued the NuTide:323 study following a steering committee recommendation. This decision may impact investor sentiment negatively in the short term. However, ongoing studies NuTide:701 and NuTide:303 show promise, which could mitigate negative impacts.
The discontinuation of the NuTide:323 study could lead to a negative short-term impact on NuCana's stock price due to potential concerns about the study's results. However, the continuation and promising data from the NuTide:701 and NuTide:303 studies could help offset some of the negative sentiment, as they indicate ongoing progress in other areas of the company's research.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100